Bcl-2 is a proto-oncogene, the expression product of which is suspected as the motivator for cancers and autoimmune diseases by activating superfluous cells (Roy et al., 2014). The human Bcl-2 gene has two main promoters, P1 and P2, both of which regulate the initiation of gene transcription (Dexheimer et al., 2006). P1 is a GC-rich promoter in which i-motif structures have been reported in vitro (Amato et al., 2022). Previous studies proved that G4 structures provide a negative signal, resulting in the silencing of gene expression (Brooks and Hurley, 2009). In contrast, the i-motif in the Bcl-2 P1 promoter is a positive signal to activate gene transcription (Kang et al., 2014).

The small molecule ligand biproline amide derivative PBP1 (2, Figure 2) specifically binds the Bcl-2 i-motif, which promotes folding of the C-rich DNA sequence into i-motif structure at neutral pH and up-regulating Bcl-2 expression in both RNA and protein synthesis. Its isomer PBP2 (3, Figure 2) has a lower affinity for the Bcl-2 i-motif and reduces the level of active caspase enzymes 3/7 in HCT-116 cells in flow cytometry analysis (Debnath et al., 2017). Yang et al. (2020) reported that the natural flavonoids P5 and P6 (4, 5, Figure 2) had a higher affinity for the Bcl-2 i-motif compared to P1 (6, Figure 2). The acridone derivative A22 (7, Figure 2) (Li et al., 2020) stimulated Bcl-2 expression, reducing hepatocyte apoptosis and alleviating inflammation, endoplasmic reticulum stress, and cirrhosis in a NAFLD/NASH (non-alcoholic fatty liver disease/non-alcoholic steatohepatitis) model. Thus, A22 (7) may be a promising compound for the treatment of liver illnesses. In the quest for therapy for diffuse large B cell lymphoma (DLBCL), Kendrick et al. (2017) proposed an innovative strategy to simultaneously use GQC-05 and IMC-76 (8, Figure 2), which respectively recognize the Myc G4 and the Bcl-2 i-motif. This treatment not only regulated Myc and Bcl-2 gene expression but also significantly decelerated tumor growth in DLBCL xenografted mice.

hnRNP LL (heterogeneous nuclear ribonucleoprotein LL) protein, which shows tissue-specific distribution, activates T cells by transferring the transcriptional genome and then advances cell proliferation and inhibits cell death (Oberdoerffer et al., 2008). Roy et al. (2016) defined hnRNP LL as an active transcription factor for Bcl-2, which recognizes the i-motif by binding the preferred loop to its four RRM (RNA recognition motif). Among the four RRMs, RRM1 and RRM2 strongly combine with the Bcl-2 i-motif to drive the i-motif transformation into a more stable hairpin structure and finally upregulate Bcl-2 transcription. Furthermore, the small molecule IMC-48 (9, Figure 2) increased i-motif and hnRNP LL levels by binding the central ring of the i-motif. In contrast, IMC-76 (8) wrapped flexible hairpins to decrease the levels of this compound (Cui et al., 2014; Kendrick et al., 2014).

Located in the human chromosome at 4q12-13, the c-kit proto-oncogene is a key point in cancer occurrence and proliferation (Abdel-Magid, 2021). The transcriptional product of c-kit is a type III receptor tyrosine kinase, which participates in regulating hematopoietic stem cell proliferation and differentiation. Recent findings have shown that c-kit mutations are strongly related to the morbidity and prognosis of gastrointestinal stromal tumors, small-cell lung cancer, melanoma, and systemic mastocytosis (Pathania et al., 2021). Given the overexpression of c-kit gene in some diseases, targeting and inhibiting c-kit expression is considered a novel strategy.

Through spectroscopic analysis, Bucek and his team (2009; 2010) reported the presence of i-motif-forming sequences in the c-kit promoter, where G4s and i-motifs coexist with duplexes at pH values of 3 to 6.5. Additionally, compounds such as terpyridine derivatives (Wei and Gao, 2015), trisubstituted isoalloxazines (Bejugam et al., 2007), and benzo[a]phenoxazine derivatives (McLuckie et al., 2011) have high affinities for c-kit G4s.

As a human proto-oncogene, c-myb plays an important role in regulating cell proliferation and differentiation in the hematopoietic and gastrointestinal systems. The c-myb mutation or overexpression induces cancerous lesions including acute myeloid leukemia and breast, colon, and gastroesophageal cancers (Gonda, 1998; Ramsay et al., 2003). Hence, it is vital to regulate c-myb expression when treating these diseases.

The c-myb G4 DNA blocks the transcriptional activity of the T7 RNA polymerase (Mishra et al., 2019). Wang et al. (2020) reported that the natural compound hyoscine butylbromide specifically bound c-myb G4 DNA with a binding constant of 1.18 × 10⁵ L/mol. There remains comparatively scarce researches on c-myb i-motifs, most of which focus on factors affecting the formation and structural stability of the c-myb i-motif. Intramolecular i-motif structures formed in a stretch of cytosine-rich sequence S6 in the transcription start site of c-myb at pH 7.0 and ions like H⁺ and K⁺ promoted the transformation of the double helix to G4/i-motif structures (Li et al., 2016). Moreover, Li et al. (2016) screened out a natural product, Fangchinoline (10, Figure 3), which combines the c-myb i-motif DNA mainly in a “1 + 1” mode with a low affinity.

The c-myc is a proto-oncogene, the protein of which widely regulates transcription (Dang et al., 2006). The c-myc expression has important implications for the metabolism and growth of cancers including adenomatous colorectal polyposis and lymphoma (Shim et al., 1997; He et al., 1998). Both c-myc G4 and i-motif structures control c-myc transcription, as demonstrated in footprinting analysis of the c-myc promoter region in vitro.

Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is closely related to chromatin remodeling, transcription, splicing, and translation (Bomsztyk et al., 2004). For c-myc, it is also a significant transcriptional activator that may speed carcinogenesis (Sutherland et al., 2016) (E)-1-(4-methoxyphenyl)-3-(4-morpholino-6-nitroquinolin-2-yl) prop-2-en-1-one (11, Figure 3) is the first-reported ligand for the hnRNP K protein. When this compound binds to hnRNP K, it induces i-motifs unfolding, resulting in c-myc downregulation. It also shows different anti-proliferative effects on human cancer cell lines, with IC₅₀ values ranging from 1.36 M to 3.59 M (Shu et al., 2019). TMPyP4 (12, Figure 3) specifically binds to the top of the i-motif structure of nuclease hypersensitivity element III1 (NHE III1) in c-myc, subsequently preventing hnRNP K from binding to c-myc and ultimately silencing c-myc (Bialis et al., 2007). According to ITC data, TMPyP4 (12) can embed itself in two adjacent C-C⁺ base pairs through π–π stacking (Figure 7). Qin et al. (2017) confirmed that TMPyP4 (12) can bind to the major external groove of the i-motif structure owing to its large steric hindrance and ionic strength (Figure 7). TMPyP4 (12) also combines with both ends of the i-motif in the presence of Van der Waals and electrostatic forces (Cashman et al., 2008) (Figure 7).

The double acridine derivative a9 (13, Figure 3), which stabilizes the c-myc promoter NHE III1 G4 and i-motif, inhibited the proliferation of lymphatic carcinoma cell lines, including Raji and CA46, and limited the clone formation and migration of the SiHa human cervical squamous cell line. And the IC₅₀ of these two lymphatic carcinoma cell lines are 3.385 μM and more than 50 μM respectively (Kuang et al., 2020). ActD (Actinomycin D) (14, Figure 3) binds non-specifically to the duplex DNA and unwinds it, after which ActD (14) preferentially binds to G4 DNA by terminal stacking, with a binding constant of 1.34 × 10⁵ M^-1 at pH 7.2. However, the binding constant of ActD (14) and c-myc i-motif is only 9.3 × 10⁴ M^-1 at pH 5, which is the weakest constant among three non-B DNA conformations (Niknezhad et al., 2016).

The RAS gene family is one of the most widespread proto-oncogenes and includes KRAS, NRAS, and HRAS. HRAS transmits signals to the nucleus and stimulates cell proliferation (Lowy, 1993). Miglietta et al. (2015) proved that the lateral loops of the HRAS i-motif provide binding sites for the RRM domains of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). After hnRNP A1 stably binds to the i-motif sequence, gene transcription is activated. Compounds 1 and 2 (15, 16, Figure 3) show sub-micromolar affinities for the HRAS i-motif (Table 1), which is a C-rich sequence located upstream of the HRAS oncogene transcription start site. Compound 1 (15) is assumed to directly bind to the i-motif core region, while compound 2 (16) binds to the minor loop region (Journey et al., 2018).

Among the RAS gene family, KRAS is a frequently mutated oncogene with specific frequencies of variation in different cancer types. KRAS hyperactivation often results in sustained tumor proliferation, mostly common in lung, colorectal, and pancreatic carcinomas (Friday and Adjei, 2005; Baines et al., 2011; Cox et al., 2014). Thus, researchers have identified small molecule inhibitors with anticancer activity to treat KRAS-driven cancers (Kumar and Priya Doss, 2021a; Kumar and Priya Doss, 2021b; Udhaya Kumar et al., 2022).

While studies on the KRAS i-motif are insufficient, it is clear that the C-rich nucleic acid sequences in the KRAS promoter can form i-motifs, which are in a state of dynamic transition with hairpin species (Manzini et al., 1994; Amato et al., 2022). HnRNP K can bind selectively to the KRAS i-motif and upregulate KRAS transcription. Kaiser et al. (2017) showed that nitidine (17, Figure 3), a benzophilite alkaloid, is preferred to bind hairpin species in the central loop region of KRAS i-motifs (Figure 7). The cross-link between hnRNP K and i-motif is then destroyed, following with refolding of the i-motif and increasing gene transcription. Nitidine (17) also stabilized KRAS G4s and microscale thermophoresis analysis showed that it decreased KRAS expression in pancreatic cancer cells (Morgan et al., 2016). Thus, nitidine (17) plays a dual role in i-motif and G4s, providing a distinct mechanism for drug development.

Brown et al. (2017) reported that the nuclease hypersensitivity element (NHE) in the human PDGFR promoter could form an i-motif structure. The R1 mutation (T-to-C) in the PDGFR i-motif, increased the thermal stability of the i-motif (ΔT = 13.2 °C). NSC309874 (18, Figure 3) preferentially bound to the R1-mutated i-motif in medium-flux screening and finally downregulated gene expression in neuroblastoma cells.

The acridone derivative B19 (19, Figure 3) selectively induced i-motif formation at the c-myc promoter and downregulated its transcription, eventually causing apoptosis in cancer cells (Shu et al., 2018). Since the compound showed insufficient anticancer activity, Zhang et al. (2021) modified it into the acridone naphthalide derivative WZZ02 (20, Figure 3). In vitro experiments showed that WZZ02 (20) exhibited the specificity of stabilizing the G4 located in the PDGFR promoter and the potential to disrupt the complementary i-motif structure, leading to PDGFR downregulation in a dose-dependent manner. WZZ02 (20) also showed excellent anticancer activity in the MCF-7 xenograft tumor model by inducing cell apoptosis and cycle arrest and inhibiting proliferation, likely due to its intricate interaction with PDGFR G4 and i-motif. Hence, WZZ02 (20) may be a potential agent for cancer therapy.

The cell cycle checkpoint protein RAD17 is directly involved in the cellular DNA damage and replication detection system, playing a critical role in maintaining genomic stability and carcinogenesis (Zhou et al., 2013). While limited work has assessed i-motifs located in the RAD17 promoter sequence, the structure of the RAD17 i-motif changes rapidly when the pH drops, without observable hysteresis (Rogers et al., 2018).

The RET proto-oncogene encodes the receptor tyrosine kinase and is crucial for neurodevelopment. Most commonly, RET mutations cause two neural crest disorders, Hirschsprung’s disease and multiple endocrine neoplasia type 2 (Manié et al., 2001). Stable G4 and i-motif structures can form within the subterminal promoter region of human RET (Huppert and Balasubramanian, 2007). A fluorescent cytosine analog, 1,3-diaza-2-oxophenothiazine used as a pH probe showed DNA forming double strands at higher pH while shaping i-motifs in acidic environments. The RET i-motif also showed a higher anisotropic signal; thus, this system can be used to monitor reversible pH changes in the design of molecular logic gates and intricate biosensors (Bielecka and Juskowiak, 2015; Bielecka et al., 2019).

Vascular endothelial growth factor (VEGF) is a diffusible endothelial cell-specific mitogen and angiogenic factor and the major regulator of physiological angiogenesis irreplaceable for embryonic development and disease progression. Additionally, VEGF mRNA upregulation is associated with angiogenesis in most common human tumors and proliferative retinopathy. Thus, resisting VEFG is considered an effective strategy for the treatment of neoplasms and retinopathy (Ferrara, 1995; Matsumoto and Ema, 2014).

Guo et al. (2008) reported the presence of intramolecular i-motif structures in the poly C region of the proximal end of the VEGF promoter. In the context of epigenetics, accompanied by the cytosine-phosphate-guanine (CpG) methylation, VEGF i-motif structures could be more stable (Kimura et al., 2022). With the help of a DNA methylation detection system, Yoshida et al. (2016) showed decreased DNA polymerase efficiency with increased DNA methylation in VEGF i-motif sequences, indicating that the i-motif formation sequence may inhibit gene expression by increasing methylation. Takahashi et al. (2020) showed that the plant flavonol fisetin (Fis) (21, Figure 3) preferred to combine with the VEGF i-motif and provoked i-motif unfolding. Moreover, the fluorescence emission spectra showed that Fis (21) bound to the central ring of the VEGF i-motif.

Telomerase maintains the integrity of chromosome ends and is important in cell immortalization and carcinogenesis. Human telomerase mainly consists of three different subunits, among which the catalytic subunit hTERT is the rate-limiting determinant of telomerase activity. The hTERT expression is sensitized when carcinogenesis occurs. However, this expression is regulated not only by various activators and inhibitors but also epigenetic pathways like DNA methylation and histone modification (Takakura et al., 1999; Daniel et al., 2012).

Initially, TMPyP4 (12) was identified as a specific ligand for hTERT G4s (Fedoroff et al., 2000). Later, NMR spectroscopy results from Fernández et al. (2011) showed that TMPyP4 (12) also advances the formation of the h-telo (human telomeric) i-motif DNA structure in a non-intercalation mode. Pagano and colleagues (2018) showed that existing G4 ligands, including BRACO-19, mitoxantrone, phen-DC3, pyridostatin, and RHPS4 (22-26, Figure 4) also interact with the h-telo i-motif. Moreover, BRACO-19 (22), mitoxantrone (23), and phen-DC3 (24) destabilize the h-telo i-motif. However, Wright and his team (2016) reported the opposite finding, likely due to the different experimental conditions, in which mitoxantrone (23) firmly bound to the i-motif and induced its formation at pH 5.5. As mitoxantrone (23) is a well-known topoisomerase II inhibitor for the treatment of non-Hodgkin lymphoma and metastatic breast cancer and slowing the progression of multiple sclerosis, the mechanisms by which mitoxantrone (23) combines with the i-motif require urgent study.

[Tb ₂ ( _DL -Cys) ₄ (H ₂ O) ₈ ]Cl ₂ and [Tb ₂ ( _DL -HVal) ₄ (H ₂ O) ₈ ]Cl ₆ .2H ₂ O (27, 28, Figure 4) are terbium amino acid complexes that can bind not only h-telo G4s but also i-motifs without conformational changes (Xu et al., 2006). The models for the interactions between the h-telo i-motif and a ruthenium (II) polypyridine compound (29, Figure 5) are complicated. Especially, the cis isoform (30, Figure 5) can bind the major groove of the h-telo i-motif more tightly due to its smaller spatial structure compared to the mer (31, Figure 5) and trans (32, Figure 5) isoforms. Three isoforms combine with the i-motif in different ways: the Λ-cis has 68 contacts with the i-motif core, only 52 in Δ-cis, and even fewer in the mer (31) and trans (32) isoforms. In addition, luminescence lifetime data supported that the cis (30) isoform can be used as a small molecule to detect death-associated protein (DAP) i-motifs (Spence et al., 2020).

Sheng et al. (2017) reported that thiazole orange (TO) (33, Figure 6) stabilized the h-telo i-motif no matter the sequence, therefore available as probes in i-motif DNA analysis. Moreover, they identified several novel i-motif-binding ligands, including tobramycin, alexidine, tilorone, chlorhexidine, phenazopyridine, amodiaquine, harmalol, quinalizarin, and minocycline tyrothricin (34-42, Figure 6). Recent research is lacking regarding how these compounds interact with i-motifs; thus, further exploration is needed. Slightly interacting with i-motif DNA, [Ru(bpy) ₂ (dppz)] ²⁺ (43, Figure 6) preferentially binds the h-telo G4 sequence and can act as a “photoswitch” to monitor the dynamic transition of G4 DNA structures (Shi et al., 2010).

Berberine (44, Figure 6) binds to the h-telo i-motif structure via electrostatic interactions, with a weak dissociation constant (Table 1) (Xu et al., 2016; Gargallo et al., 2021). Berberine (44) can also be used as an effective fluorescent probe to monitor the conformational conversion of i-motifs driven by pH (Xu et al., 2016). Absorption titration and thermodynamic analyses showed that phenanthroline compounds 1–3 (45-47, Figure 6) bind to the C-C⁺ base pairs of telomeric i-motifs in the presence of π-π stacking, intercalation, or hydrophobic interaction. These compounds show a higher affinity for G4 DNA compared to the i-motif, which is attributed to telomeric G4s having larger π-π stacking interactions and van der Waals contacts (Wang et al., 2013). The 1,8-, 1,4-, 1,5-, and 2,6-disubstituted anthraquinone monomers (48-51, Figure 6) were investigated to assess their effects on the thermal stability of the i-motif. When anthraquinones modify the TAA loop of the h-telo DNA sequence in the intercalation or external binding mode, the melting temperature increases significantly, accordingly enhancing the stability of the i-motif structure (Gouda et al., 2017).

In their analysis of structure-activity relationships, Wei et al. (2015) reported that the coumarin group may be the determinant of the specific affinities of terpyridine derivatives 1–3 (52-54, Figure 6) for the h-telo i-motif, among which terpyridine derivative 1 (52) reduced 88.7% of the telomerase activity and slightly restrained the bioactivity of topoisomerase I activity at 5 μmol/L. Moreover, macrocyclic bis-acridine (BisA) (55, Figure 6) shows a considerable affinity for the telomeric i-motif. While BisA (55) did not show obvious effects on the physiological function and conformation of telomeric i-motifs (Bonnet et al., 2022).

In addition, chemically modified cytosines have different effects on the formation of i-motif structures under physiological conditions. The telomeric i-motif became less stable at a neutral pH due to the methylated cytosine in MCF7 and MCF10A cell lines (Wright et al., 2020). Xu et al. (2015) also reported that the telomeric i-motif was stable with small amounts of cytosine methylation modification. However, numerous hydroxymethylation and methylation modifications could lead to structural destabilization. In plants, cytosine methylation is similarly meaningful in the epigenetic regulation of telomeric DNA (Školáková et al., 2020), which can also fine-tune the stability and the pH dependence of i-motifs. Balasubramaniyam et al. (2021) reported that the halogenation of cytosine at C5 accelerated i-motif folding, which eventually altered the pH dependence. Moreover, the hydrophilic hydroxyl group at C5 is more tolerant to immunostimulation compared to the hydrophobic methyl group (Kandimalla et al., 2001). Therefore, modifying the deoxycytidine or cytidine of i-motifs may be a new strategy to regulate immunity in vivo.

The synthetic C6T i-motif has two unequal broad grooves and is used to explore possible binding modes with compounds with long molecular structures such as polyamines. Putrescine (56, Figure 9) with the shortest molecular length, only binds to the loop region (Figure 7) and, thus, has the lowest affinity for i-motifs. In contrast, the longer molecule spermidine (57, Figure 9) can bind the loop region and the groove; therefore, it has two quite different binding constants. The longest molecule, spermine (58, Figure 9), can simultaneously bind two broad grooves of the C6T i-motif, with the highest binding affinity (Molnar et al., 2019) (Table 1). Based on mechanisms of polyamine binding to i-motifs, additional research is needed to identify additional ligands with greater affinity by altering the molecular length of the polyamines. Kinetic analysis has shown that the addition of 5′-terminal guanidino-i-clamp (Tsvetkov et al., 2019) or i-clamp (Tsvetkov et al., 2018) can decrease the unfolding rate of synthetic i-motifs, which guarantees the stability of i-motifs. It is also possible to become unstable given the steric hindrance.

Additionally, BmPOUM2 has been reported to be a significant regulator of the wing disc cuticle protein gene, namely, BmWCP4. Silkworms cannot complete metamorphosis when the BmPOUM2 is expressed. An i-motif structure and the novel BmILF i-motif-binding protein have been identified. BmILF specifically binds the i-motif and activates BmPOUM2, which prevents silkworm metamorphosis into moths (Niu et al., 2018). For agriculturists, these findings provide new insights into the epigenetic mechanism for how to control the growth of silkworms to achieve a high silk yield.

The above summary showed that natural i-motif structures are mainly located in the promoter regions of various oncogenes. Hence, most current studies on the biological function of i-motifs have focused on how to build targeted and effective anticancer strategies through the combination of i-motif and other molecules. Therefore, attention to genes with very few or no drug studies, such as c-kit, c-myb, RAD17, and RET, may demonstrate the value and application of i-motifs in the medical field. We hold a strong belief that i-motifs in promoters can be subtly regulated by ligands under specific conditions to stabilize or disrupt their structures and, ultimately, regulate their biological functions.

DM is often accompanied by cardiovascular complications like coronary heart disease, which is a common reason for clinical death (Rogowicz-Frontczak et al., 2012). Therefore, it is particularly urgent to treat diabetes. The insulin minisatellite region is the insulin-linked polymorphic region (ILPR), the polymorphism length of which is strongly linked to the genetic susceptibility of insulin-dependent diabetes mellitus (IDDM) (Catasti et al., 1996). The C-rich duplex sequence in ILPR forms intermolecular/intramolecular i-motifs through pairing between C⁺ and C (Jolad et al., 2005; Dhakal et al., 2012). Catasti et al. (1997) suggested that the stable folding of the i-motif in C-rich sequences led to the loose structure upstream of the insulin gene, promoting insulin expression. Dhakal et al. (2010) indicated that, simply from a mechanical perspective, when insulin i-motifs interact with RNA polymerases, the unfolding force of the i-motif is greater than the stall force, interrupting gene transcription (Galburt et al., 2007).

Experimental results at the cellular and individual levels will reveal whether insulin i-motifs advance or inhibit insulin transcription and provide more therapeutic options for patients with DM. Thus, more studies are needed on i-motifs in the human insulin gene at these levels.

HIV-1 is a human immunodeficiency virus and a basic pathogen of acquired immunodeficiency syndrome (AIDS) (Radestock et al., 2013). The i-motif structure can also form in the promoter of the HIV-1 DNA genome. Moreover, the i-motif located in the long terminal repeat (LTR) of the HIV-1 promoter has a unique folding pattern that differs from that in the human genome. Ruggiero et al. (2019) reported that hnRNP K induces the formation of the HIV-1 LTR i-motif and subsequently represses the transcription, finally decreasing the virulence of HIV-1. These findings lay a theoretical foundation for innovative antiviral drug design based on the selective recognition of the HIV-1 i-motif.

Depression is a neuropsychiatric disorder strongly associated with the serotonin transporter (SERT). The linkage polymorphic region of SERT contains two C-rich allelic variants that regulate susceptibility to depression by altering SERT expression levels. Both variants can form i-motifs; however, the mechanism requires further exploration (Zhang et al., 2015; Thorne et al., 2021). As a key regulator of serotonin, i-motifs in the SERT-linkage polymorphic region will be an important pharmacological breakthrough for treating depression.

Fragile X syndrome (FXS) is the most common consequence of genetic intellectual disability caused by the CGG/CCG tandem repeat sequences of Fragile X Messenger Ribonucleoprotein 1 (FMR1) on the X chromosome. CCG repeats prefer to form stable intermolecular i-motif structures (Tekendo-Ngongang et al., 2021; Zhang et al., 2022). Chen et al. (2018) reported that when the CCG trinucleotide repeat region is bound to the Co^II (Chro) ₂ dimer (59, Figure 9), the i-motif unfolds and is restored the double-helix structure, suggesting that Co^II (Chro) ₂ (59) could be a new drug for the treatment or diagnosis of neurological diseases.

In addition, hexanucleotide repeat amplification sequence G4C2 in the C9orf72 gene is the most common single genetic factor for frontotemporal dementia and amyotrophic lateral sclerosis. G4C2 can fold into unusual secondary structures, including R-loops, i-motifs, and G4s (Kumar et al., 2016). These findings indicate that i-motifs can be a new target in gene therapy for neuropsychiatric disorders.

Tumor occurrence is often accompanied by gene mutations. Any gene abnormality, such as the inactivation of the anti-oncogene or the activation of the proto-oncogene can cause cancer. Recent reports have demonstrated the central role of Bcl-2 in orchestrating the interplay between apoptosis and senescence. Bcl-2 over-activation results in the abnormal proliferation of cancer cells (Nahta and Esteva, 2003; Kim et al., 2004). As one of the most important transcription factors, c-myc protein is particularly significant for the reprogramming of multiple types of cancer cells, as well as their proliferation and chemoresistance (Fatma et al., 2022). The c-myc inactivation can lead to sustained tumor regression, which may be a key therapy to reverse cancerous growth and restore antitumor immune responses in patients with high c-myc expression (Dhanasekaran et al., 2022). Additionally, telomeres and VEGF play vital roles in indefinite proliferation and nutrient supply, which are essential for tumor growth.

As i-motifs form in specific regions of most oncogenes, a link must exist between cancer development and therapy. As mentioned above, researchers often establish specialized models, screen and modify drugs with certain cytotoxicity, and use the effects between drugs and i-motif to verify the anticancer potential of the studied drugs. For example, in the anti-DLBCL model, IMC-76 (8) was found to bind the Bcl-2 i-motif and upregulate Bcl-2 expression, thus slowing cancer cell growth (Kendrick et al., 2017). In the anti-lymphoid Raji cell line model, a9 (13) interacted with the c-myc i-motif and showed high cytotoxic effects, with an IC₅₀ reaching 3.385 μM (Kuang et al., 2020). In the cancer model associated with VEGF, Fis (21) was used as a probe to specifically recognize the VEGF i-motif; therefore, this system can be used to diagnose VEGF-associated cancers (Takahashi et al., 2020). In the cancer model associated with telomeres, terpyridine derivative 1 (52) binds to the h-telo i-motif to inhibit telomerase and topoisomerase activity (Wei and Gao, 2015). Table 1 summarizes studies on drugs. Although clinical studies on these potential anti-cancer drugs are lacking, those on the association of i-motifs with cancer are essential.

Since these oncogenes have been introduced above, the retinoblastoma gene Rb is highlighted here. Rb is the first tumor suppressor gene identified in humans, the functional incapacitation of which is related to retinoblastoma tumorigenesis. The product of Rb, pRB protein, controls the cell cycle transition from the G₁ to the S phase, pausing the cell cycle in a static state. Clinical findings suggest that a dysregulation of the G₁-S control pathway may occur in retinoblastoma and sporadic lung, breast, and bladder cancers (Dannenberg et al., 2000). Thus, restoring or enhancing Rb function may be a late-model strategy for these cancers. Lee et al. (2015) identified the Rb i-motif based on the pH, providing evidence for retinoblastoma diagnosis. Studies on the structural characteristics, biological functions, and targeted ligands of i-motifs in RB are scarce (Xu and Sugiyama, 2005) and require future exploration.

In addition to these diseases, i-motifs also have specific roles in fighting bacterial infections. Hemiprotonic phenanthroline-phenanthroline⁺ compounds are synthesized based on the unique structure of half-protonated nucleotide base pairs of the i-motif DNA from oncogenes. These compounds not only selectively resist tumors but also have broad-spectrum antibacterial activity, providing new therapeutic candidate drugs for patients with cancer accompanied by infection (Zhao et al., 2022).

The diseases discussed in this review are i-motif-related. Among these diseases, cancer is a primary focus. The study of these diseases should consider the following four aspects: the specific gene locus of the i-motif, the effect of i-motif formation on the disease, pathways involved in the i-motif regulation of the disease, and different drug design schemes for different signaling molecules (Figure 8). As described above, current research on these diseases is still lacking. Therefore, additional research on this topic is needed.